Navigation Links
Taligen Therapeutics Secures Series B Financing
Date:2/1/2008

AURORA, Colo., Feb. 1 /PRNewswire/ -- Taligen Therapeutics, Inc. today announced it anticipates receiving up to $65 million in a tranched Series B financing. The financing was led by Alta Partners and Clarus Ventures with participation from existing investors, including Sanderling Ventures, Tango and High Country Venture.

"This Series B round represents not only an infusion of capital but the addition of two world class investor groups, Alta Partners and Clarus Ventures, represented on our Board respectively by Edward Hurwitz and Nicholas Galakatos, PhD," said Timothy Mills, PhD, Chairman of the Board of Taligen. "The progress made since our original investment in 2005 now allows us to develop multiple products to control the alternative pathway of complement activation. With this additional funding, we expect to move into clinical development with all of our lead candidates."

About Taligen: Founded in 2004, Taligen Therapeutics, Inc. is a development-stage biotechnology company with novel technology and expertise focused on modulation and control of the complement system. The complement system is believed to be a critical component in the initiation of inflammation. Complement system activation is characteristic of many human diseases, including asthma, macular degeneration, rheumatoid arthritis and immune renal disease.

Taligen's lead products are monoclonal antibodies and recombinant fusion proteins which target key factors in the alternative complement pathway. These products are in preclinical stages of development to treat systemic as well as local inflammatory conditions.

The Company was founded by Drs. Woodruff Emlen and V. Michael Holers based on technology and intellectual property predominantly from the University of Colorado at Denver and Health Sciences Center (UCDHSC) and partnering institutions. Dr. Holers is currently Professor of Medicine at UCDHSC and Dr. Emlen is a former Professor of Medicine and Immunology at U
'/>"/>

SOURCE Taligen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
2. CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008
3. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
4. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
5. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
6. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
10. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
11. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ov.25/PRNewswire/--Formanybusinesses,2009hasbeenap...ndfastestgrowingnetworkofexpertphysiciansspecializ...rmones has grownthenumberof physiciansinitsnetwo...inprogresstoaddmorephysician-ownedcenters,includin...styear ,BodyLogicMDhasopened13newbioidenticalhormo...
(Date:11/24/2009)...German . , Whether it,s CD packaging, contai...quency Identification) are increasingly finding th...to label objects or goods and identify them automa...r can read and process the data contained in the l...roduction conditions of up to 100 degrees Celsius....
(Date:11/24/2009)...o,Nov.24/PRNewswire-FirstCall/--DowAgroSciencesCan...ds,adivisionofThompsonsLimitedofBlenheim,Ontario.T...ences,currentseedsbusinessasthecompanyanticipatest...oSciencesHerbicideTolerantTraitTechnologyincornin2.... ,, "Thisacquisitionbringstogethertwostrongpro...
(Date:11/24/2009)...e-Asia/--NODPharmaceuticalsInc.announced,theUSPate...icationfor,itsnano-particleoraldeliveryorNODtechno...chtoincorporatepeptidesor,proteinsintobio-adhesive...eadministeredasinjections.NODtechnologyisaplatform...gssuchasinsulin,interferon,growthhormone,exenatid...
Breaking Biology Technology:Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Intelligence inside metal components 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3
...ons has,long been used as a marketing tool by the ...bility to reach consumers has never been greater. ...joined the traditional press,release as effective ...his,understanding, new research was conducted by B...ns activities are most effective at educating,and ...
...ytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) announ...nterim results of a U.S. Phase II trial investigat...and soft tissue sarcomas metastatic to,the lung is...nstitute of,Drug Development (IDD), the Cancer The...s Health Science Center, (UTHSC), San Antonio, Tex...
...d its annual "Power of Partnership" award to Baxte...cal device and specialty pharmaceutical,company. B...ibution,Management Association,s (HDMA) Annual Lea...Power of Partnership" award was created by AmeriCa...d distribution organizations that have,shown excep...
Other Biology Technology:New Study Shares Best Practices in Biopharma Public Relations 2Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data 2Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data 3AmeriCares Presents 'Power of Partnership' Award to Baxter 2AmeriCares Presents 'Power of Partnership' Award to Baxter 3
(Date:11/26/2009)... Aureus ) and other drug-resistant bacteria could ...ype devices have been developed to offer safe, qui... Two prototype devices have been developed: one fo...ds and feet) in hospitals and public spaces where ...shoot bacteria-killing agents into infested chroni...
(Date:11/25/2009)...ers and ambulance workers faced a terrifying rescu...attled to save people from the collapsing Twin Tow...cuated as many people as they could in an area whi...g their jobs even harder was the problem of poor c...ves jammed mobile networks with calls and the emer...
(Date:11/25/2009)...ors recently received funding from the National Sc...cial to understanding the environment. The three g...ssistant professor in the Department of Biological...ate research projects. , His first project, titl...unctions from the Leaf to the Landscape," will exa...
Breaking Biology News(10 mins):Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Magic box for mission impossible 2Magic box for mission impossible 3Kent State University professors focus research on the environment with grants totaling $890,000 2Bonus Payout Trends and Continuing Cost Controls Reflect Challenging Business Climate Says Aon Consultings Radford 48659 1Bonus Payout Trends and Continuing Cost Controls Reflect Challenging Business Climate Says Aon Consultings Radford 48659 2Bonus Payout Trends and Continuing Cost Controls Reflect Challenging Business Climate Says Aon Consultings Radford 48659 3Bonus Payout Trends and Continuing Cost Controls Reflect Challenging Business Climate Says Aon Consultings Radford 48659 4Actuaries Weigh in on Ways to Address Risk Exposures and Challenges with the U S Health Care System 48656 1Actuaries Weigh in on Ways to Address Risk Exposures and Challenges with the U S Health Care System 48656 2Actuaries Weigh in on Ways to Address Risk Exposures and Challenges with the U S Health Care System 48656 3Actuaries Weigh in on Ways to Address Risk Exposures and Challenges with the U S Health Care System 48656 4Cornflakes White Bread Could Boost Heart Risk 48653 1Cornflakes White Bread Could Boost Heart Risk 48653 2Cornflakes White Bread Could Boost Heart Risk 48653 3
...ook For Biometrics Revenue and Profit Growth, WAL...Bulletin Board: BKYI), a leader in wireless public...solutions, today announced its,financial results f...tal revenue from continuing operations for the thr...n representing a 27% decrease from the,$3.0 millio...
...a. --- The observation that males evolve more quic...y biologist Charles Darwin noted the majesty of a ...ness of the peahens. , No matter the species, mal...elodious warbles in an eternal competition to win ...n. , Why males are in evolutionary overdrive even...
...s prepare to discuss conservation-friendly carbon ...s a new wave of deforestation in the South America...t Anglia and Brazils Goeldi Museum highlights once...n forest. , Working in the north-eastern Brazili...ertook the single-largest assessment of the biodiv...
Other Biology News:BIO-key Reports Third Quarter 2007 Results 2BIO-key Reports Third Quarter 2007 Results 3BIO-key Reports Third Quarter 2007 Results 4BIO-key Reports Third Quarter 2007 Results 5Simple reason helps males evolve more quickly 2Simple reason helps males evolve more quickly 3Single-largest biodiversity survey says primary rainforest is irreplaceable 2
...I in both reduced and non-reduced forms. It does n...actor XII. Factor XIII is a Beta-globulin found in...II-A is the catalytic subunit and is a dimmer of M... Alpha2Beta2 heterodimer (M.W. 320kDa); whereas in...
Anti-CaMKII (Calmodulin-dependent Protein Kinase II) Monoclonal Antibody, Unconjugated, Clone 6G9 (2) from CHEMICON
Rabbit Anti-Ca2+ Channel Ca gamma 2 Polyclonal Antibody, Unconjugated from BD Biosciences Pharmingen
Goat Anti-Human Centaurin alpha 2 Antibody, Unconjugated from Novus Biologicals
Biology Products: